Vascular Endothelial Growth Factor A Regulates the Secretion of Different Angiogenic Factors in Lung Cancer Cells

Journal of Cellular Physiology

Volumn 231, Issue 7, 2016, Pages 1514-1521

  Frezzetti, Daniela ^a   Gallo, Marianna ^a   Roma, Cristin ^a   D'Alessio, Amelia ^a   Maiello, Monica R ^a   Bevilacqua, Simona ^a   Normanno, Nicola ^a   De Luca, Antonella ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 2; BECAPLERMIN; CD31 ANTIGEN; FOLLISTATIN; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 8; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; RAS PROTEIN; RECOMBINANT VASCULOTROPIN; RECOMBINANT VASCULOTROPIN A; SCATTER FACTOR; STAT3 PROTEIN; UNCLASSIFIED DRUG; ANGIOGENIC PROTEIN; RECOMBINANT PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

A549 CELL LINE; ANGIOGENESIS; ARTICLE; AUTOCRINE EFFECT; CANCER GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; H1975 CELL LINE; HCC827 CELL LINE; INTRACELLULAR SIGNALING; LUNG CANCER CELL LINE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; ANIMAL; BIOSYNTHESIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL MOTION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANGIOGENIC PROTEINS; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84947975931     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.25243     Document Type: Article

References (30)

1. Alevizakos M, Kaltsas S, Syrigos KN. 2013. The VEGF pathway in lung cancer. Cancer Chemother Pharmacol 72:1169-1181.
2. Bonnesen B, Pappot H, Holmstav J, Skov BG. 2009. Vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 expression in non-small cell lung cancer patients: Relation to prognosis. Lung Cancer 66:314-318.
3. Chae SS, Kamoun WS, Farrar CT, Kirkpatrick ND, Niemeyer E, de Graaf AM, Sorensen AG, Munn LL, Jain RK, Fukumura D. 2010. Angiopoietin-2 interferes with anti-VEGFR2-induced vessel normalization and survival benefit in mice bearing gliomas. Clin Cancer Res 16:3618-3627.
4. Chatterjee S, Heukamp LC, Siobal M, Schottle J, Wieczorek C, Peifer M, Frasca D, Koker M, Konig K, Meder L, Rauh D, Buettner R, Wolf J, Brekken RA, Neumaier B, Christofori G, Thomas RK, Ullrich RT. 2013. Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer. J Clin Invest 123:1732-1740.
5. Crawford Y, Ferrara N. 2009. Tumor and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol Sci 30:624-630.
6. Crino L, Metro G. 2014. Therapeutic options targeting angiogenesis in nonsmall cell lung cancer. Eur Respir Rev 23:79-91.
7. De Luca A, Gallo M, Aldinucci D, Ribatti D, Lamura L, D'Alessio A, De Filippi R, Pinto A, Normanno N. 2011. Role of the EGFR ligand/receptor system in the secretion of angiogenic factors in mesenchymal stem cells. J Cell Physiol 226:2131-2138.
8. De Luca A, Lamura L, Gallo M, Maffia V, Normanno N. 2012. Mesenchymal stem cell-derived interleukin-6 and vascular endothelial growth factor promote breast cancer cell migration. J Cell Biochem 113:3363-3370.
9. De Luca A, Roma C, Gallo M, Fenizia F, Bergantino F, Frezzetti D, Costantini S, Normanno N. 2014. RNA-seq analysis reveals significant effects of EGFR signalling on the secretome of mesenchymal stem cells. Oncotarget 5:10518-10528.
10. Gallo M, De Luca A, Lamura L, Normanno N. 2012. Zoledronic acid blocks the interaction between mesenchymal stem cells and breast cancer cells: Implications for adjuvant therapy of breast cancer. Ann Oncol 23:597-604.
11. Goel HL, Mercurio AM. 2013. VEGF targets the tumor cell. Nat Rev Cancer 13:871-882.
12. Grepin R, Guyot M, Jacquin M, Durivault J, Chamorey E, Sudaka A, Serdjebi C, Lacarelle B, Scoazec JY, Negrier S, Simonnet H, Pages G. 2012. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/avastin treatment: The role of CXCL cytokines. Oncogene 31:1683-1694.
13. Harper SJ, Bates DO. 2008. VEGF-A splicing: The key to anti-angiogenic therapeutics? Nat Rev Cancer 8:880-887.
14. Holopainen T, Saharinen P, D'Amico G, Lampinen A, Eklund L, Sormunen R, Anisimov A, Zarkada G, Lohela M, Helotera H, Tammela T, Benjamin LE, Yla-Herttuala S, Leow CC, Koh GY, Alitalo K. 2012. Effects of angiopoietin-2-blocking antibody on endothelial cell-cell junctions and lung metastasis. J Natl Cancer Inst 104:461-475.
15. Jantus-Lewintre E, Sanmartin E, Sirera R, Blasco A, Sanchez JJ, Taron M, Rosell R, Camps C. 2011. Combined VEGF-A and VEGFR-2 concentrations in plasma: Diagnostic and prognostic implications in patients with advanced NSCLC. Lung Cancer 74:326-331.
16. Jia H, Cheng L, Tickner M, Bagherzadeh A, Selwood D, Zachary I. 2010. Neuropilin-1 antagonism in human carcinoma cells inhibits migration and enhances chemosensitivity. Br J Cancer 102:541-552.
17. Karkkainen MJ, Petrova TV. 2000. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Oncogene 19:5598-5605.
18. Kerbel RS. 2008. Tumor angiogenesis. N Engl J Med 358:2039-2049.
19. Li H, Takayama K, Wang S, Shiraishi Y, Gotanda K, Harada T, Furuyama K, Iwama E, Ieiri I, Okamoto I, Nakanishi Y. 2014. Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression. Cancer Chemother Pharmacol 74:1297-1305.
20. Naumov GN, Nilsson MB, Cascone T, Briggs A, Straume O, Akslen LA, Lifshits E, Byers LA, Xu L, Wu HK, Janne P, Kobayashi S, Halmos B, Tenen D, Tang XM, Engelman J, Yeap B, Folkman J, Johnson BE, Heymach JV. 2009. Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance. Clin Cancer Res 15:3484-3494.
21. Normanno N, De Luca A, Maiello MR, Campiglio M, Napolitano M, Mancino M, Carotenuto A, Viglietto G, Menard S. 2006. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 207:420-427.
22. Price DJ, Miralem T, Jiang S, Steinberg R, Avraham H. 2001. Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 12:129-135.
23. Relf M, LeJeune S, Scott PA, Fox S, Smith K, Leek R, Moghaddam A, Whitehouse R, Bicknell R, Harris AL. 1997. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57:963-969.
24. Ribatti D. 2011. Novel angiogenesis inhibitors: Addressing the issue of redundancy in the angiogenic signaling pathway. Cancer Treat Rev 37:344-352.
25. Weis SM, Cheresh DA. 2011. Tumor angiogenesis: Molecular pathways and therapeutic targets. Nat Med 17:1359-1370.
26. Wu Y, Hooper AT, Zhong Z, Witte L, Bohlen P, Rafii S, Hicklin DJ. 2006. The vascular endothelial growth factor receptor (VEGFR-1) supports growth and survival of human breast carcinoma. Int J Cancer 119:1519-1529.
27. Yuan A, Lin CY, Chou CH, Shih CM, Chen CY, Cheng HW, Chen YF, Chen JJ, Chen JH, Yang PC, Chang C. 2011. Functional and structural characteristics of tumor angiogenesis in lung cancers overexpressing different VEGF isoforms assessed by DCE- and SSCE-MRI. PLoS ONE 6:e16062.
28. Yuan A, Yu CJ, Kuo SH, Chen WJ, Lin FY, Luh KT, Yang PC, Lee YC. 2001. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol 19:432-441.
29. Zhao M, Gao FH, Wang JY, Liu F, Yuan HH, Zhang WY, Jiang B. 2011. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 73:366-374.
30. Zygalaki E, Tsaroucha EG, Kaklamanis L, Lianidou ES. 2007. Quantitative real-time reverse transcription PCR study of the expression of vascular endothelial growth factor (VEGF) splice variants and VEGF receptors (VEGFR-1 and VEGFR-2) in non small cell lung cancer. Clin Chem 53:1433-1439.